NEW YORK, Aug. 4 -- Merck & Co. (MRK) reported second-quarter revenue of $16.607 billion on Monday, up 5 percent from a year earlier, and simultaneously disclosed that the Food and Drug Administration had approved LIPFENDRA, its once-daily oral PCSK9 inhibitor, the first pill of its class cleared for patients with persistently high LDL cholesterol.

The two events converged on the same trading day, offering investors and patients a simultaneous view of the pharmaceutical direction Merck has been building toward through a multibillion-dollar acquisition campaign launched in late 2025. For patients who have relied on injectable alternatives such as Amgen's Repatha or Sanofi's Praluent to manage coronary risk, LIPFENDRA represents an oral on...